Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Physiopathology, Diagnosis and Therapy of Primary Cephalalgia and Adaptive Disorders

Biomarker Identification to Predict the Evolution of Migraine From an Episodic to a Chronic Condition

The main aim of the present pilot study is to prove the possibility to use the Nitroglycerin (NTG) model to describe the pathophysiology of headache using task-free advanced Magnetic Resonance Imaging (MRI) techniques, in order to depict the static changes of the ictal and inter-ictal phase of migraine attacks vs the pain free state in healthy subjects and to compare that with the spontaneous headache attack experienced by chronic migraineurs.

Studie Overzicht

Toestand

Voltooid

Conditie

Gedetailleerde beschrijving

Resting state functional magnetic resonance imaging (rs-fMRI) has depicted cyclical functional connectivity changes during the ictal and inter-ictal phase of the migraine attack. In this pilot study, Functional Connectivity (FC) changes during nitroglycerin (NTG) induced migraine attacks were assessed vs the pain-free condition in healthy subjects.

To this end, subjects with episodic migraine (EM) without aura were enrolled. NTG-triggered a spontaneous-like migraine attack in the subjects. They underwent 4 rs-fMRI scan repetitions during different phases of the attack (baseline, prodromal, full blown, recovery phase) with a 3 Tesla MR scanner. According to the pain field literature, several regions of interests were studied, in particular the thalamic areas and the salience network (SN) were selected as primary areas of interest for the analyses. Subjects' rs-fMRI data were first processed with a seed-based correlation analysis (SCA) to assess the static changes in FC between the thalamus and the rest of the brain during the experiment. The wavelet coherence approach (WCA) were also applied to test the changes in time-in-phase coherence between the thalamus and the salience network (SN).

Healthy subject were administered nitroglycerin as well and scanned at a pain free baseline and after 3 hours in order to compare the response.

The rebound headache that followed acute drug withdrawal were used as a surrogate paradigm of spontaneous attack. Patients with chronic migraine and medication overuse were hospitalized for a supervised withdrawal program at the Mondino Foundation; during the program if they experienced a rebound headache attack, they were scanned with a rs-fMRI acquisition.

The acquired imagines were analyzed with the same procedure regarding the evaluation of static and dynamic functional connectivity fluctuation.

Studietype

Observationeel

Inschrijving (Werkelijk)

15

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Pavia, Italië, 27100
        • Headache Science Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 60 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Subjects with episodic migraine without aura; patients with chronic migraine and medication overuse; healthy subjects

Beschrijving

Episodic migraineurs

Inclusion Criteria:

  • age between 18-60 years;
  • diagnosis of episodic migraine without aura developed before the age of 50;
  • no current prophylactic treatment for migraine prevention;
  • chronic migraineurs with medication overuse according to the ICHDIII criteria

Exclusion Criteria:

  • chronic or medication-overuse headache or cluster headache diagnosis;
  • any chronic pain condition or disorders other than migraine;
  • an alleged diagnosis of major psychiatric disorders such as depression, bipolar affective disorder and schizophrenia;
  • a diagnosis of tension type headache with a frequency of more than 5 days per month;
  • any cardiovascular diseases in which the NTG use could be contraindicated;
  • blood pressure hypotension, closed angle glaucoma, anaemia;
  • women in child bearing, breast feeding; continuous use of benzodiazepines;
  • any neuroradiological pathological findings at a previous MRI scan of the head.

Chronic migraineurs

Inclusion Criteria:

  • age between 18-60 years;
  • diagnosis of migraine without aura developed before the age of 50 according to the ICHD III criteria;
  • currently chronic migraineurs with medication overuse according to The International Classification of Headache Disorders 3rd edition (ICHDIII) criteria.

Exclusion Criteria:

  • any chronic pain condition or disorders other than migraine;
  • an alleged diagnosis of major psychiatric disorders such as depression, bipolar affective disorder and schizophrenia;
  • a diagnosis of tension type headache with a frequency of more than 5 days per month;
  • any cardiovascular diseases in which the NTG use could be contraindicated;
  • blood pressure hypotension, closed angle glaucoma, anaemia; women in child bearing, breast feeding;
  • continuous use of benzodiazepines;
  • any neuroradiological pathological findings at a previous MRI scan of the head.

Healthy subjects

Inclusion Criteria:

  • age between 18-60 years;
  • overall good clinical condition, no neurological findings at the physical examination.

Exclusion criteria:

  • history of episodic or chronic or medication-overuse headache or cluster headache diagnosis according to the International Chronic Headache Disease (ICHD) III criteria;
  • any chronic pain condition or disorders other than migraine;
  • an alleged diagnosis of major psychiatric disorders such as depression, bipolar affective disorder and schizophrenia;
  • a diagnosis of tension type headache with a frequency of more than 5 days per month;
  • any cardiovascular diseases in which the NTG use could be contraindicated;
  • blood pressure hypotension, closed angle glaucoma, anaemia;
  • women in child bearing, breast feeding;
  • continuous use of benzodiazepines;
  • any neuroradiological pathological findings at the baseline MRI scan of the head.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Chronic migraineurs
This group includes patients with chronic migraine.
Control group
This group includes healthy subjects.
Episodic migraineurs
This group includes patients with episodic migraine

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Functional Connectivity (FC) changes
Tijdsspanne: Up to 6 hours
Functional connectivity pattern of changes profiling the different condition of the migraine experience. To depict the static and dynamics changes of brain activity during a migraine attack; ii) To validate the use of the NTG-induced attacks paradigm as a reliable instrument combined with an fMRI approach to compare the induced vs the spontaneous attack; iii) To describe possible differences in brain activity between attacks in chronic and episodic migraineurs.
Up to 6 hours

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Magnetic Resonance Imaging (MRI)
Tijdsspanne: Up to 6 hours
To acquire sufficient MRI to identify feature patterns that can profile patient's condition using machine learning (ML) and deep learning (DL) algorithms. This can be achieved by combining clinical, psychological, biological, neurophysiological and MRI-derived features into a multimodal multi-parametric approach suitable for patient's classification. The ML and DL approaches could also be adopted to predict chronification, as well as the response to a withdrawal program for medication overuse headache.
Up to 6 hours
Monthly migraine frequency (day/month)
Tijdsspanne: Up to 6 hours
To acquire clinical data to identify feature patterns that can profile patient's condition using machine learning (ML) and deep learning (DL) algorithms.
Up to 6 hours
Disease duration (years)
Tijdsspanne: Up to 6 hours
To acquire clinical data to identify feature patterns that can profile patient's condition using machine learning (ML) and deep learning (DL) algorithms.
Up to 6 hours
Nausea (number)
Tijdsspanne: Up to 6 hours
As a feature of the migraine attack.To acquire clinical data to identify feature patterns that can profile patient's condition using machine learning (ML) and deep learning (DL) algorithms.
Up to 6 hours
Vomiting (number)
Tijdsspanne: Up to 6 hours
As a feature of the migraine attack.To acquire clinical data to identify feature patterns that can profile patient's condition using machine learning (ML) and deep learning (DL) algorithms.
Up to 6 hours
Photophobia (number)
Tijdsspanne: Up to 6 hours
As a feature of the migraine attack.To acquire clinical data to identify feature patterns that can profile patient's condition using machine learning (ML) and deep learning (DL) algorithms.
Up to 6 hours
Phonophobia (number)
Tijdsspanne: Up to 6 hours
To acquire clinical data to identify feature patterns that can profile patient's condition using machine learning (ML) and deep learning (DL) algorithms.
Up to 6 hours
Aggravation by movement (number)
Tijdsspanne: Up to 6 hours
As a feature of the migraine attack. To acquire clinical data to identify feature patterns that can profile patient's condition using machine learning (ML) and deep learning (DL) algorithms.
Up to 6 hours
Throbbing pain (number)
Tijdsspanne: Up to 6 hours
As a feature of the migraine attack. To acquire clinical data to identify feature patterns that can profile patient's condition using machine learning (ML) and deep learning (DL) algorithms.
Up to 6 hours
Abortive medication (number of intake/month)
Tijdsspanne: Up to 6 hours
To acquire clinical data to identify feature patterns that can profile patient's condition using machine learning (ML) and deep learning (DL) algorithms.
Up to 6 hours

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

31 augustus 2018

Primaire voltooiing (Werkelijk)

31 maart 2019

Studie voltooiing (Werkelijk)

15 december 2020

Studieregistratiedata

Eerst ingediend

21 december 2020

Eerst ingediend dat voldeed aan de QC-criteria

5 januari 2021

Eerst geplaatst (Werkelijk)

6 januari 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 januari 2021

Laatste update ingediend die voldeed aan QC-criteria

5 januari 2021

Laatst geverifieerd

1 november 2020

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren